Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling

Author

SIN, Sang-Hoon^{1 2} ; ROY, Debasmita^{1 2} ; LING WANG^{1 2} ; STAUDT, Michelle R^{1 2} ; FAKHARI, Farnaz D^{1 2} ; PATEL, Dhavalkumar D^{1 2 3 4} ; HENRY, David^{5 6} ; HARRINGTON, William J^{7 8} ; DAMANIA, Blossom A^{1 2} ; DITTMER, Dirk P^{1 2}
[1] Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, United States
[2] Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, United States
[3] Department of Medicine, University of North Carolina at Chapel Hill, United States
[4] Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, United States
[5] Department of Medicine, University of Pennsylvania, Philadelphia, United States
[6] Joan Karnell Cancer Center, University of Pennsylvania, Philadelphia, United States
[7] Sylvester Cancer Center, University of Miami, FL, United States
[8] Department of Medicine, University of Miami, FL, United States

Source

Blood. 2007, Vol 109, Num 5, pp 2165-2173, 9 p

ISSN

0006-4971

Scientific domain

Medical oncology; Hematology

Publisher

The Americain Society of Hematology, Washington, DC

Publication country

United States

Document type

Article

Language

English

Keyword (fr)

Anticancéreux Hématologie In vivo Lignée cellulaire établie Lymphome primitif séreuse Sirolimus Transduction signal Hémopathie lymphoïde B Hémopathie maligne Inhibiteur synthèse protéique Lactone Lymphome non hodgkinien Lymphoprolifératif syndrome Macrocycle Macrolide

Keyword (en)

Antineoplastic agent Hematology In vivo Established cell line Primary effusion lymphoma Sirolimus Signal transduction B cell neoplasm Malignant hemopathy Protein synthesis inhibitor Lactone Non Hodgkin lymphoma Lymphoproliferative syndrome Macrocycle Macrolide

Keyword (es)

Anticanceroso Hematología In vivo Línea celular establecida Linfoma primario de cavidades Sirolimús Transducción señal Hemopatía maligna Inhibidor síntesis proteica Lactona Linfoma no Hodgkin Linfoproliferativo síndrome Macrociclo Macrólido

Classification

Pascal

002 Biological and medical sciences / 002B Medical sciences / 002B19 Hematologic and hematopoietic diseases / 002B19B Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis

Discipline

Blood diseases

Origin

Inist-CNRS

Database

PASCAL

INIST identifier

18581893

Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS